Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272415
Status:
TERMINATED
Last Update Posted:
2009-03-11
First Post:
2006-01-03
Brief Title:
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability Safety and Pharmacokinetics in Patients With Melanoma
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase Ib Open-Label Multicenter Trial of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate the Tolerability Safety and Pharmacokinetics in Subjects With Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma
Status:
TERMINATED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective open-label non-randomized multicenter study in adults aged eighteen 18 or older with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma A maximum of 18 subjects will be enrolled in Stage 1 of this study Stage 1 completed enrollment in June 2006 A maximum of 39 subjects will be enrolled in Stage 2 of this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| INO4136g | None | None | None |